Cohen, Jordana B.; Gadde, Kishore M. published the artcile< Weight Loss Medications in the Treatment of Obesity and Hypertension>, Related Products of 96829-58-2, the main research area is review antiobesity agent weight loss obesity hypertension; Blood pressure; Hypertension; Obesity; Weight loss; Weight loss medication; Weight loss pharmacotherapy.
A review. Purpose of Review: Weight loss is strongly associated with improvement in blood pressure; however, the mechanism of weight loss can impact the magnitude and sustainability of blood pressure reduction Recent Findings: Five drugs-orlistat, lorcaserin, liraglutide, phentermine/topiramate, and naltrexone/bupropion-are currently approved for weight loss therapy in the USA. Naltrexone/bupropion results in an increase in in-office and ambulatory blood pressure compared to placebo. Other therapies are associated with modest lowering of blood pressure, and are generally well-tolerated; nonetheless, evidence is limited regarding their effect on blood pressure, particularly longitudinally, in individuals with hypertension. Summary: Although weight loss medications can be an effective adjunct to lifestyle modifications in individuals with obesity, there is limited evidence regarding their benefit with regard to blood pressure. Future studies evaluating the effectiveness of weight loss medications should include careful assessment of their short- and long-term impact on blood pressure in individuals with hypertension.
Current Hypertension Reports published new progress about Antiobesity agents. 96829-58-2 belongs to class amides-buliding-blocks, and the molecular formula is C29H53NO5, Related Products of 96829-58-2.
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics